Raiffeisen Switzerland Cooperative Stock

Certificat

NQLRCH

CH1282074900

Market Closed - Bid/Ask 11:20:00 2024-06-28 am EDT			After market 11:15:00 am
103.4 ^CHF	+0.03%		103.8	+0.31%

3 months

+0.51%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart Raiffeisen Switzerland Cooperative

Latest news about ELI LILLY AND COMPANY

Pfizer moves forward with once-daily weight loss drug	06:49am	RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating	06:33am	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating	06:33am	MT
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating	06:33am	MT

More news

Static data

Product type	Reverse Convertibles
Buy / Sell	CALL
Underlying	ELI LILLY AND COMPANY
Issuer	Raiffeisen Switzerland B.V.
	NQLRCH
ISIN	CH1282074900
Date issued	2024-01-26
Strike	639.2 $
Maturity	2025-07-29 (383 Days)
Parity	1 : 1
Emission price	100 CHF
Emission volume	N/A
Settlement	both
Currency	CHF

Technical Indicators

Highest since issue	104.4 CHF
Lowest since issue	101.6 CHF
Spread	8.3 CHF
Spread %	0.80%

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company